161 related articles for article (PubMed ID: 30870506)
1. Cost-minimization analysis of GSTP1c.313A>G genotyping for the prevention of cisplatin-induced nausea and vomiting: A Bayesian inference approach.
Macedo LT; Ferrari VE; Carron J; Costa EFD; Lopes-Aguiar L; Lourenço GJ; Lima CSP
PLoS One; 2019; 14(3):e0213929. PubMed ID: 30870506
[TBL] [Abstract][Full Text] [Related]
2. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Ando Y; Hayashi T; Ito K; Suzuki E; Mine N; Miyamoto A; Oya M; Matsuda H; Isaji A; Nakanishi T; Imaizumi K; Shibata T; Okada T; Sakurai K; Naito K; Uyama I; Kawada K; Takahashi H; Yamada S
Support Care Cancer; 2016 Feb; 24(2):871-878. PubMed ID: 26206077
[TBL] [Abstract][Full Text] [Related]
3. Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature.
Becherini C; Salvestrini V; Desideri I; Vagnoni G; Bonaparte I; Bertini N; Mattioli C; Angelini L; Visani L; Scotti V; Livi L; Caini S; Bonomo P
Radiol Med; 2024 Mar; 129(3):457-466. PubMed ID: 38351333
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Moore S; Tumeh J; Wojtanowski S; Flowers C
Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
[TBL] [Abstract][Full Text] [Related]
5. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract][Full Text] [Related]
6. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
Tsukahara K; Nakamura K; Motohashi R; Sato H; Endo M; Katsube Y; Ueda Y; Suzuki M
Acta Otolaryngol; 2014 Nov; 134(11):1198-204. PubMed ID: 25315920
[TBL] [Abstract][Full Text] [Related]
7. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
[TBL] [Abstract][Full Text] [Related]
8. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong.
Chan SL; Jen J; Burke T; Pellissier J
Asia Pac J Clin Oncol; 2014 Mar; 10(1):80-91. PubMed ID: 24571059
[TBL] [Abstract][Full Text] [Related]
10. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
11. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
Van Belle SJ; Cocquyt V
Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
[TBL] [Abstract][Full Text] [Related]
12. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1977-85. PubMed ID: 18042005
[TBL] [Abstract][Full Text] [Related]
13. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
[TBL] [Abstract][Full Text] [Related]
14. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
18. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
19. Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients.
Kono T; Ueda T; Takumida M; Furuie H; Hamamoto T; Takeno S; Hirakawa K
Acta Otolaryngol; 2018 Oct; 138(10):921-925. PubMed ID: 30016902
[TBL] [Abstract][Full Text] [Related]
20. Why do we need another antiemetic? Just ask.
Kris MG
J Clin Oncol; 2003 Nov; 21(22):4077-80. PubMed ID: 14559888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
